Drug Approval | July 15, 2022
U.S. FDA grants emergency use authorization for Novavax COVID-19 vaccine
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
